Changzhou Liren Pharmaceutical Co., Ltd. was established in 2016 and is headquartered in Changzhou. It is a high-tech enterprise specializing in the research and development of pharmaceutical raw materials and intermediates, as well as large-scale production.

The company has strong R&D capabilities and has established two R&D centers in Changzhou, dedicated to the development of active pharmaceutical ingredients and intermediates, equipped with multiple advanced experimental equipment and precision detection instruments. The R&D team is led by four PhDs and consists of multiple experienced researchers, possessing full process R&D capabilities from product route screening, small-scale development to pilot scale production. At the same time, the company has established long-term and stable industry university research cooperation relationships with several well-known domestic universities, continuously improving the efficiency of technological innovation and achievement transformation.

In terms of production, the company's active pharmaceutical ingredient factory located in Jiangsu strictly follows GMP standards and has passed compliance inspections and obtained audit recognition from multiple customers. The intermediate production base is located in Shandong, Inner Mongolia, Ningxia and other places. Each factory focuses on different types of chemical reactions and can efficiently undertake chlorination, fluorination, bromination, cyanation, hydrogenation and various conventional reactions, achieving flexible and efficient capacity allocation and collaborative production.

Changzhou Liren Pharmaceutical Co., Ltd. always adheres to innovation as the core driving force, upholds the business principle of "honesty and trustworthiness, quality first", practices the development concept of "high-precision, short and fast", and continuously strengthens its core competitiveness. The company has independent qualifications for foreign trade operations, which enables it to better serve customers at home and abroad, continuously pursue excellence, and work together with partners to achieve common development and breakthroughs.